Price
$13.67
Decreased by -2.36%
Dollar Volume
2.84 M
ADR%
6.45
Earnings Report Date (estimate)
Mar 8, 23 (-0.74)
Market Cap.
375.94 M
Shares Float
14.21 M
Shares Outstanding
27.50 M
Beta
0.87
Price / Earnings
-2.38
BPR
868.86
20D Range
12.97 16.28
50D Range
8.04 16.28
200D Range
2.36 16.28
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 10, 22 -0.87
Decreased by -42.62%
-0.92
Increased by +5.43%
Aug 9, 22 -0.86
Increased by +83.90%
-1.01
Increased by +14.85%
May 12, 22 -1.18
Increased by +84.47%
-0.73
Decreased by -61.64%
Mar 10, 22 -11.00
Decreased by -2.40 K%
-0.66
Decreased by -1.57 K%
Nov 10, 21 -0.61
Decreased by -8.93%
-0.77
Increased by +20.78%
Aug 9, 21 -5.34
Decreased by -907.55%
-1.82
Decreased by -193.41%
May 13, 21 -7.60
Decreased by -1.42 K%
-0.15
Decreased by -4.97 K%
Mar 11, 21 -0.44
Increased by +20.00%
-0.37
Decreased by -18.92%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-12.00 M
Decreased by -52.42%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-11.25 M
Decreased by -50.68%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-15.32 M
Increased by +90.99%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-9.49 M
Decreased by -5.71%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-7.87 M
Increased by +27.54%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-7.47 M
Increased by +21.48%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-170.08 M
Decreased by -2.04 K%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-8.98 M
Decreased by -35.82%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.